Adverse Event Reports From Acorda Languished As Long As 100 Days, FDA Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA warning letter says the company did not report all complaints about the lack of efficacy of its muscular sclerosis drug Ampyra.